2011 - 2012

2012

  • Maria Sjöberg appointed Chief Scientific Officer
  • Maria Öhlander appointed Head of Clinical Development
  • Eprotirome’s phase III program is terminated

2011

  • Agreement reached with Pfizer for the RORgamma project for autoimmune diseases.
  • Henrik Palm appointed Chief Financial Officer.
  • Eprotirome outlicensed to Indian Alkem Laboratories Ltd for development into dyslipidemia in in India and certain other Asian countries.
  • Göran Wessman new chairman of the board.
  • Karo Bio initiates the AKKA study, a phase III trial with eprotirome on patients with Heterozygous Familial Hypercholesterolemia (HeFH).
  • Per Bengtsson appointed President and CEO
  • Preparations are initiated to spin off the preclinical operations